AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

AbbVie will present clinical data for ABBV-1480 (RC148), a PD-1/VEGF bispecific antibody, in the frontline non-small cell lung cancer (NSCLC) setting via an oral presentation. The update also includes new data and program progress for telisotuzumab adizutecan (Temab-A) and the ABBV-706 platform. With no efficacy/safety figures cited here, the near-term impact is likely limited until the disclosed trial results are reviewed.

Analysis

AbbVie will present clinical data for ABBV-1480 (RC148), a PD-1/VEGF bispecific antibody, in the frontline non-small cell lung cancer (NSCLC) setting via an oral presentation. The update also includes new data and program progress for telisotuzumab adizutecan (Temab-A) and the ABBV-706 platform. With no efficacy/safety figures cited here, the near-term impact is likely limited until the disclosed trial results are reviewed.